Asterias Biotherapeutics to Report First Quarter 2018 Results on May 9, 2018
03 mai 2018 16h01 HE
|
Asterias Biotherapeutics
FREMONT, Calif., May 03, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American:AST), a biotechnology company dedicated to developing cell-based therapeutics to treat neurological...
Asterias Biotherapeutics to Present Safety and Efficacy Data from AST-OPC1 SCiStar Study at the American Spinal Injury Association (ASIA) 2018 Annual Meeting
02 mai 2018 08h44 HE
|
Asterias Biotherapeutics
FREMONT, Calif., May 02, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE MKT:AST), a biotechnology company dedicated to developing cell-based therapeutics to treat neurological...
Asterias Biotherapeutics to Present AST-OPC1 Program Update at the Upcoming American Society for Neural Therapy and Repair Conference
27 avr. 2018 07h00 HE
|
Asterias Biotherapeutics
FREMONT, Calif., April 27, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE MKT:AST), a biotechnology company dedicated to developing cell-based therapeutics to treat neurological...
Asterias Announces Clinical Grade Lot Released to Support Dosing of First Subjects in First Clinical Study of AST-VAC2
25 avr. 2018 07h00 HE
|
Asterias Biotherapeutics
FREMONT, Calif., April 25, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American:AST), a biotechnology company dedicated to developing cell-based therapeutics to treat neurological...
Asterias Biotherapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Recent Developments
15 mars 2018 16h10 HE
|
Asterias Biotherapeutics
- Achieved Meaningful Progress with Key Clinical Programs - - Anticipate Multiple Data Readouts from SCiStar Study in 2018 into First Quarter of 2019 - - Expect to Enroll First Subject in AST-VAC2...
Asterias Biotherapeutics to Report Fourth Quarter and Full Year 2017 Results on March 15, 2018
09 mars 2018 07h00 HE
|
Asterias Biotherapeutics
FREMONT, Calif., March 09, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American:ST), a biotechnology company dedicated to developing cell-based therapeutics to treat neurological...
Asterias Provides Update for its AST-OPC1 Phase 1/2a Clinical Trial in Severe Spinal Cord Injury
28 févr. 2018 16h10 HE
|
Asterias Biotherapeutics
- Results to Date Show AST-OPC1’s Favorable Safety Profile, Potential for Cell Engraftment and Improved Motor Function - - Multiple Additional Data Readouts from SCiStar Study Expected in 2018 into...
Asterias Expands Global IP Portfolio with New Patents, Including Key Additional Patent Protection for its Cancer Immunotherapy Program
15 févr. 2018 07h00 HE
|
Asterias Biotherapeutics
FREMONT, Calif., Feb. 15, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American:AST), a biotechnology company dedicated to developing regenerative medicine therapeutics to treat...
Asterias Biotherapeutics Reports Milestone Targets for 2018
04 janv. 2018 07h52 HE
|
Asterias Biotherapeutics
FREMONT, Calif., Jan. 04, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American:AST), a biotechnology company pioneering the field of regenerative medicine, today provided its 2018...
Asterias Biotherapeutics Completes Enrollment of Entire SCiStar Study
19 déc. 2017 07h00 HE
|
Asterias Biotherapeutics
FREMONT, Calif., Dec. 19, 2017 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE MKT:AST), a biotechnology company pioneering the field of regenerative medicine, today announced enrollment...